(Total Views: 301)
Posted On: 07/12/2018 4:27:00 PM
Post# of 72445
Topical 50% PASI75 drug deal
www.fiercebiotech.com/biotech/dermavant-inks-330m-deal-for-gsk-s-phase-3-ready-psoriasis-drug
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
by Amirah Al Idrus | Jul 12, 2018 11:08am
Vivek Ramaswamy
Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), has been tested as a topical treatment in more than 800 patients. (Roivant)
Dermavant handed over £150 million ($198 million) up front, with a potential £100 million ($132 million) in development milestone payments up for grabs. Under the deal, slated to close in the second half of this year, Dermavant will assume all global rights to tapinarof, except in China, GSK said in a statement.
Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), has been tested as a topical treatment in more than 800 patients in phase 1 and 2. In a dose-ranging study involving 227 adults with plaque psoriasis, tapinarof brought about "clinically meaningful, dose-dependent improvements." After 12 weeks, about half of the patients receiving a once-daily dose of either tapinarof 1% or 0.5% had a 75% or greater improvement in a psoriasis severity score. Only 5% of placebo patients hit this mark.
www.fiercebiotech.com/biotech/dermavant-inks-330m-deal-for-gsk-s-phase-3-ready-psoriasis-drug
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
by Amirah Al Idrus | Jul 12, 2018 11:08am
Vivek Ramaswamy
Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), has been tested as a topical treatment in more than 800 patients. (Roivant)
Dermavant handed over £150 million ($198 million) up front, with a potential £100 million ($132 million) in development milestone payments up for grabs. Under the deal, slated to close in the second half of this year, Dermavant will assume all global rights to tapinarof, except in China, GSK said in a statement.
Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), has been tested as a topical treatment in more than 800 patients in phase 1 and 2. In a dose-ranging study involving 227 adults with plaque psoriasis, tapinarof brought about "clinically meaningful, dose-dependent improvements." After 12 weeks, about half of the patients receiving a once-daily dose of either tapinarof 1% or 0.5% had a 75% or greater improvement in a psoriasis severity score. Only 5% of placebo patients hit this mark.
(0)
(0)
